Gut Bacteria Discovery Opens a New Probiotic Path for Lupus Treatment

Researchers at UT Health San Antonio have identified what they describe as the first potential probiotic treatment for systemic lupus erythematosus, an autoimmune disease in which the immune system attacks healthy tissues and can damage the skin, joints, kidneys, blood vessels and other organs. The study, published in Nature Communications, found that people with lupus had reduced levels of the beneficial gut bacterium Faecal bacterium prausnitzii, while their gut microbes appeared to shift away from digesting dietary fibre and toward using host-derived sugars linked to inflammation and disease activity. In lupus mouse models, supplementation with a specific strain, F. prausnitzii UT1, helped restore healthier gut-microbiome function and reduced markers of disease progression, suggesting that future lupus care may not depend only on suppressing the immune system but could also involve rebuilding protective microbial balance in the gut. The discovery is still early and has not yet become an approved human treatment, but it is important because many lupus patients need safer long-term options that reduce inflammation without weakening the body's defences too severely. If future clinical trials confirm the findings, this research could mark a shift toward microbiome-guided autoimmune treatment, where restoring the right bacteria becomes part of calming an overactive immune system.